AI Article Synopsis
- The ongoing Ebola virus outbreak is larger and more impactful worldwide than previous incidents, highlighting the need for effective treatments.
- Currently, there are no approved antiviral treatments for Ebola, making it urgent to quickly develop and test new antiviral options.
- The World Health Organization has prioritized several antiviral candidates, including AVI-6002, BCX4430, and others, and this review provides an update on their development and patent status.
Article Abstract
The current Ebola virus outbreak is unprecedented in its scope and international impact. Given that there are currently no approved antivirals to treat Ebola virus, there is urgency to conduct more rapid development and evaluation of Ebola antivirals. Recently, the World Health Organization identified a number of antivirals as high priority to include AVI-6002 (AVI-7537 and AVI-7539), BCX4430, brincidofovir, favipiravir, and TKM-100802. This review describes these chemically synthesized inhibitors of Ebola virus, relevant patent development and gives an update on their current status.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1574891x10666150326114221 | DOI Listing |
Publication Analysis
Top Keywords
ebola virus
16
current status
8
chemically synthesized
8
synthesized inhibitors
8
inhibitors ebola
8
ebola
5
status chemically
4
virus
4
virus current
4
current ebola
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!